Parmax Pharma Stock Screener | Share Price & Fundamental Analysis
PARMAX
Pharmaceuticals
Screen Parmax Pharma share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹32.19
▲
0.91 (2.91%)
Market Cap
₹11.69 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
-2.15
EPS (TTM)
₹-5.60
Dividend Yield
-
Debt to Equity
-
52W High
₹48.94
52W Low
₹29.67
Operating Margin
-27.00%
Profit Margin
-31.25%
Revenue (TTM)
₹16.00
EBITDA
₹-3.00
Net Income
₹-5.00
Total Assets
₹19.00
Total Equity
₹-2.00
Parmax Pharma Share Price History - Stock Screener Chart
Screen PARMAX historical share price movements with interactive charts. Analyze price trends and patterns.
Parmax Pharma Company Profile - Fundamental Screener
Screen Parmax Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for PARMAX shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE240T01014
Parmax Pharma Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen PARMAX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 19 | 15 | 18 | 18 | 23 | 21 | 20 | 17 | 8 | 5 |
| Current Assets | 10 | 6 | 8 | 7 | 10 | 9 | 9 | 9 | 4 | 2 |
| Fixed Assets | 8 | 9 | 10 | 10 | 11 | 10 | 5 | 6 | 3 | 3 |
| Liabilities | ||||||||||
| Total Liabilities | 19 | 15 | 18 | 18 | 23 | 21 | 20 | 17 | 8 | 5 |
| Current Liabilities | 8 | 6 | 5 | 5 | 6 | 5 | 5 | 2 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | -2 | 0 | 6 | 6 | 6 | 5 | 5 | 5 | 5 | 5 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | -6 | -4 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
Screen PARMAX income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 16 | 28 | 11 | 16 | 18 | 26 | 21 | 12 | 12 | 0 | 0 |
| Expenses | 19 | 28 | 14 | 13 | 16 | 23 | 19 | 11 | 11 | 0 | 0 |
| EBITDA | -3 | 0 | -3 | 2 | 3 | 4 | 2 | 1 | 1 | 0 | 0 |
| Operating Profit % | -27.00% | 1.00% | -31.00% | 15.00% | 14.00% | 13.00% | 8.00% | 9.00% | 9.00% | 0.00% | 0.00% |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 0 | 0 |
| Interest | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -5 | -2 | -6 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | -5 | -2 | -6 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| EPS | -12.70 | -5.60 | -34.56 | -0.28 | 0.38 | 2.02 | 1.15 | 0.21 | 0.00 | -0.02 | -0.01 |
Parmax Pharma Cash Flow Screener - Liquidity Fundamentals
Screen PARMAX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -1 | 0 | 0 | 1 | 4 | 3 | 1 | 4 | -1 | 0 |
| Investing Activities | -1 | -2 | -1 | -2 | -3 | -2 | -3 | -4 | 0 | 0 |
| Financing Activities | 1 | 1 | 0 | -1 | 0 | 0 | 3 | 1 | 1 | 0 |
| Net Cash Flow | 0 | 0 | -1 | -2 | 1 | 0 | 1 | 1 | 0 | 0 |
Screen PARMAX shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.80% | 30.83% | 30.80% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 63.09% | 63.10% | 63.10% | 63.12% | 62.90% | 65.78% | 65.34% | 65.43% |
| Other Holding | 6.11% | 6.10% | 6.10% | 6.08% | 6.29% | 3.42% | 3.83% | 3.77% |
| Shareholder Count | 2,399 | 2,377 | 2,356 | 2,334 | 2,246 | 2,185 | 2,099 | 2,002 |
Parmax Pharma Dividend Screener - Share Yield Analysis
Screen PARMAX dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Parmax Pharma Index Membership - Market Screener Classification
Screen PARMAX by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Parmax Pharma Market Events Screener - Corporate Actions
Screen PARMAX market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -3.64% | ||
| Annual General Meeting | NA | 11.04% | ||
| 2025-11-17 | 2025-11-17 | Quarterly Result Announcement | NA | -1.84% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | 2.12% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -1.09% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | -5.75% |
| 2024-11-14 | 2024-11-14 | Quarterly Result Announcement | NA | 4.73% |
Parmax Pharma Competitors Screener - Peer Comparison
Screen PARMAX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 416,501 | 40.16 | 54,729 | 9.71% | 10,980 | 46.18 |
| Divis Laboratories | 172,528 | 69.16 | 9,712 | 18.67% | 2,191 | 53.62 |
| Torrent Pharmaceuticals | 129,401 | 60.40 | 11,539 | 6.99% | 1,911 | 62.04 |
| Cipla | 120,517 | 22.30 | 28,410 | 7.12% | 5,291 | 44.91 |
| Dr Reddys Laboratories | 105,771 | 18.66 | 33,741 | 16.73% | 5,725 | 60.09 |
| Lupin | 96,151 | 22.21 | 22,910 | 13.74% | 3,306 | 60.88 |
| Zydus Life Science | 92,176 | 18.57 | 23,511 | 18.55% | 4,615 | 47.29 |
| Mankind Pharma | 90,588 | 51.90 | 12,744 | 20.90% | 2,007 | 53.62 |
| Aurobindo Pharma | 70,283 | 20.66 | 32,346 | 9.43% | 3,484 | 57.50 |
| Alkem Laboratories | 66,394 | 27.75 | 13,458 | 3.70% | 2,216 | 47.48 |
Parmax Pharma Company Announcements - News Screener
Screen PARMAX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-11-17 | Results-Delay in Financial Results | View |
| 2025-11-17 | Board Meeting Outcome for The Board Meeting Was Initially Rescheduled On November 15 2025 And Thenafter On Today I.E. November 17 2025 Hence Board Has Approved The Unaudited Financial Statements For Quarter And Half Year Ended On September 30 2025 | View |
| 2025-11-15 | Board Meeting Intimation for Reschedule Of Board Meeting Supposed To Be Held On November 14 2025 | View |
| 2025-11-08 | Board Meeting Intimation for For Approval Of Unaudited Financial Results For Quarter Ended September 30 2025 | View |
| 2025-10-29 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-02 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-10-01 | Closure of Trading Window | View |
| 2025-09-30 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-09-06 | Notice Of Thirty First Annual General Meeting Of The Company | View |
| 2025-09-06 | Reg. 34 (1) Annual Report. | View |
| 2025-08-14 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-08-14 | Financial Statements For Quarter Ended 30Th June 2025 | View |
| 2025-08-14 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-08-14 | Unaudited Financial Results For Quarter Ended 30Th June 2025 | View |
| 2025-08-14 | Board Meeting Outcome for For Approval Of Financial Results Of Quarter Ended 30Th June 2025 | View |
| 2025-08-08 | Board Meeting Intimation for Board Meeting To Be Held For Considering Unaudited Financial Statements Of The Company For Quarter Ended June 30 2025 | View |
| 2025-07-18 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-07-01 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | View |
| 2025-06-26 | Closure of Trading Window | View |